Background and aim: Primary sclerosing cholangitis (CEP) is a syndrome of unknown cause, but it may be the result of an environmental insult that occurs in patients genetically susceptible to the disease, which would indicate an autoimmune component. Aim: To describe the clinical characteristics, treatment and complications of patients with Primary Sclerosing Cholangitis
Material and methods: Design: retrospective, cross-sectional study. It was held at INNSZ during 2009-2019. 40 patients were included with the diagnosis of Primary Sclerosing Cholangitis, Both genders, ages 18-69 years. Statistic analysis: Percentages, means, medians with standard deviation were used. The X2 test was used. A value of p≤0.05 was considered statistically significant with a 95% confidence interval. The analysis was carried out using the statistical package SPSS® v. 25
Results: The number of patients was 40, male predominance in 52.5%, with a median age of 53 years and body mass index of 22.9. 22.7% of the patients had arterial hypertension and Type 2 Diabetes Mellitus as comorbidity. Cholecystectomy was the surgical antecedent in 29.5%. The predominant symptom at the time of diagnosis was jaundice in 57.5%. Primary large duct sclerosing cholangitis was observed in 92.5%, cirrhosis in 83%. and association with ulcerative colitis in 67.6%. 77% of the patients received ursodeoxycholic acid. Recurrent cholangitis presented in 37.5%. Liver transplant 30%, mortality was 12.5%, identifying as cause of death: n=2 due to complications from liver cirrhosis, n=1 due to infection, n=1 due to liver transplant complications and n=1 due to cholangiocarcinoma.
Conclusions: 1. Primary Sclerosing Cholangitis was presented predominantly in men, with a median of aged 53 years and associated with UC, 77% of the patients received medical treatment with AUDC. 2. Complications: recurrent cholangitis and dominant stenosis. 3. Liver transplant in 30%. 4. Main cause of death was due to complications associated with liver cirrhosis.
Conflicts of interest: The authors have no conflicts of interest to declare.
